![](https://d3ilqtpdwi981i.cloudfront.net/J5CuJe-bNo93Hdv61edZnuL_Lko=/0x9:520x681/425x550/smart/https://bepress-attached-resources.s3.amazonaws.com/uploads/f3/03/c1/f303c101-dc64-49b7-b76e-620253df802a/CR3.png)
Article
Patient Reported Outcomes (PROs) with Poly(ADP-ribose) Polymerase Inhibitors (PARPi) versus Chemotherapy (CTX) in Patients (pts) with Germline BRCA1/2 Mutated (gBRCA1/2mut) HER2- advanced Breast Cancer (ABC): Results from a Multi-country Real-world (RW) Study
Cancer Research / San Antonio Breast Cancer Symposium
(2021)
Abstract
A. Niyazov; K. Lewis; J. Pike; A. Rider; B. Arondekar; M. Lux
Disciplines
Publication Date
February 15, 2021
Citation Information
Reshma Mahtani. "Patient Reported Outcomes (PROs) with Poly(ADP-ribose) Polymerase Inhibitors (PARPi) versus Chemotherapy (CTX) in Patients (pts) with Germline BRCA1/2 Mutated (gBRCA1/2mut) HER2- advanced Breast Cancer (ABC): Results from a Multi-country Real-world (RW) Study" Cancer Research / San Antonio Breast Cancer Symposium Vol. 81 Iss. 4 Supplement (2021) Available at: http://works.bepress.com/reshma-mahtani/50/